$THC

BIERMAN JAMES L sold $1.2M of THC

BIERMAN JAMES L sold 5,000 shares of TENET HEALTHCARE CORP (THC) at $244.96 ($1.22M total) on 2026-07-27.

Original reporting
SEC EDGAR · BIERMAN JAMES L
Published Jul 29, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale size (5,000 shares), price ($244.96), and total proceeds ($1.2248M) reported in the Form 4.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone does not provide new fundamentals or guidance.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context on total compensation, prior sales cadence, or remaining holdings beyond the post-transaction figure.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-28 for a 2026-07-27 sale.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Tenet Healthcare director James L Bierman.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director James L Bierman filed a Form 4 selling 5,000 shares at $244.96 on 2026-07-27, totaling $1.2248M.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is an open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

No sector-level read-across provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-scheduled liquidity needs, so the signal may be weaker than headline sentiment suggests.

Key entities

  • TENET HEALTHCARE CORP

    Company whose director insider sale is disclosed on Form 4.

  • BIERMAN JAMES L

    Director who sold 5,000 shares in an open-market transaction.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.